Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Boston Trust Walden Corp

Jazz Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Boston Trust Walden cut its Jazz Pharmaceuticals stake by 4.2% in the third quarter, selling 18,554 shares; it retained 424,569 shares valued at about $98.3 million.
  • Jazz beat third-quarter revenue and earnings expectations, with revenue up 10.4% year over year, and raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion.
  • Analyst sentiment is broadly positive: Jazz has a consensus “Moderate Buy” rating and an average price target of $293.45. The company also announced a $500 million share buyback.
  • Interested in Jazz Pharmaceuticals? Here are five stocks we like better.

Boston Trust Walden Corp decreased its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 4.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 424,569 shares of the specialty pharmaceutical company's stock after selling 18,554 shares during the quarter. Jazz Pharmaceuticals comprises about 0.8% of Boston Trust Walden Corp's investment portfolio, making the stock its 24th biggest holding. Boston Trust Walden Corp owned about 0.65% of Jazz Pharmaceuticals worth $98,296,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in JAZZ. Chicago Partners Investment Group LLC grew its stake in shares of Jazz Pharmaceuticals by 3.5% in the third quarter. Chicago Partners Investment Group LLC now owns 5,513 shares of the specialty pharmaceutical company's stock worth $1,180,000 after acquiring an additional 187 shares during the last quarter. Ascent Group LLC increased its holdings in shares of Jazz Pharmaceuticals by 27.3% during the third quarter. Ascent Group LLC now owns 1,141 shares of the specialty pharmaceutical company's stock valued at $264,000 after acquiring an additional 245 shares in the last quarter. Provenance Wealth Advisors LLC purchased a new position in shares of Jazz Pharmaceuticals in the 3rd quarter worth about $514,000. Oregon Public Employees Retirement Fund raised its position in shares of Jazz Pharmaceuticals by 3.5% in the 3rd quarter. Oregon Public Employees Retirement Fund now owns 13,420 shares of the specialty pharmaceutical company's stock worth $3,107,000 after purchasing an additional 454 shares during the last quarter. Finally, XML Financial LLC raised its position in shares of Jazz Pharmaceuticals by 1.1% in the 3rd quarter. XML Financial LLC now owns 6,559 shares of the specialty pharmaceutical company's stock worth $1,519,000 after purchasing an additional 71 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company's stock.

Key Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

  • Positive Sentiment: Jazz beat Q3 revenue and earnings expectations, with growth in oncology and rare sleep products cited as drivers. The company raised its 2026 revenue outlook to roughly $4.78 billion–$4.85 billion, above the prior consensus near $4.7 billion. Q3 earnings and outlook
  • Positive Sentiment: The company announced a $500 million share buyback, which may support shareholder returns and provide demand for the stock. Share buyback announcement
  • Positive Sentiment: Several analysts raised their price targets and maintained bullish ratings after the results, including JPMorgan, Morgan Stanley, RBC and Barclays. Analyst insights
  • Neutral Sentiment: Director Bruce Cozadd sold 6,000 shares under a pre-arranged Rule 10b5-1 plan, reducing his position by 1.73%; he retained 339,875 shares after the sale. SEC filing
  • Negative Sentiment: Some coverage cautioned that slowing growth and an Actiq-related charge could temper the positive effect of the earnings beat and improved guidance. Earnings outlook risks

Insiders Place Their Bets

In related news, CEO Renée Galá sold 2,000 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $236.40, for a total value of $472,800.00. Following the completion of the sale, the chief executive officer directly owned 141,394 shares in the company, valued at approximately $33,425,541.60. This trade represents a 1.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Robert Iannone sold 76,921 shares of the business's stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $249.70, for a total value of $19,207,173.70. Following the completion of the transaction, the executive vice president directly owned 65,686 shares of the company's stock, valued at approximately $16,401,794.20. This trade represents a 53.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 100,121 shares of company stock valued at $24,632,962. 4.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

JAZZ has been the topic of a number of analyst reports. Wells Fargo & Company upped their price target on shares of Jazz Pharmaceuticals from $285.00 to $300.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 4th. Canaccord Genuity Group set a $300.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, August 26th. Barclays raised their price objective on shares of Jazz Pharmaceuticals from $271.00 to $275.00 and gave the company an "overweight" rating in a research note on Tuesday. Needham & Company LLC lifted their target price on shares of Jazz Pharmaceuticals from $292.00 to $310.00 and gave the stock a "buy" rating in a report on Wednesday, August 26th. Finally, TD Cowen upped their target price on shares of Jazz Pharmaceuticals from $275.00 to $300.00 and gave the stock a "buy" rating in a research note on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $293.45.

Read Our Latest Stock Report on Jazz Pharmaceuticals

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $234.66 on Thursday. The company has a market cap of $15.06 billion, a price-to-earnings ratio of 20.37, a P/E/G ratio of 0.46 and a beta of 0.38. The business's fifty day simple moving average is $230.15 and its two-hundred day simple moving average is $217.11. Jazz Pharmaceuticals PLC has a 12 month low of $128.80 and a 12 month high of $266.38. The company has a current ratio of 1.82, a quick ratio of 1.58 and a debt-to-equity ratio of 1.09.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share for the quarter, topping the consensus estimate of ($4.03) by $0.15. The firm had revenue of $1.24 billion during the quarter, compared to analysts' expectations of $1.21 billion. Jazz Pharmaceuticals had a return on equity of 16.88% and a net margin of 4.37%. The company's revenue was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $8.13 earnings per share. Research analysts anticipate that Jazz Pharmaceuticals PLC will post 10.84 earnings per share for the current fiscal year.

About Jazz Pharmaceuticals

(Free Report)

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz's sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.

Featured Articles

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Jazz Pharmaceuticals Right Now?

Before you consider Jazz Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jazz Pharmaceuticals wasn't on the list.

While Jazz Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines